Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605241 · ClinicalTrials.gov registry record · Phase 1
A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00605241 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 29 participants.
The verdict
NCT00605241, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders. This study will asses the effects of a single dose of GSK598809 in modulating nicotine reward in 2 cohorts of otherwise healthy male volunteers who smoke. Each cohort of subjects will receive a single dose of placebo or GSK598809 in two dosing sessions binded crossover fashine. There will be a washout period of at least seven days between each session.
Interventions
- DRUG GSK598809
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-02-25 |
| Est. Completion | 2009-03-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00605241
The ClinicalTrials.gov registry entry for NCT00605241 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK598809 is the first listed.
NCT00605241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00605241 about?
NCT00605241 is a clinical study titled "A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward". GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders. This study will asses the effects of a single dose of GSK598809 in modulating nicotine reward in 2 cohorts of otherwise healthy male volunteers who smoke. Each coho...
What is the current status of trial NCT00605241?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2008-02-25. Estimated completion is 2009-03-20.
What interventions are being tested in trial NCT00605241?
The interventions under investigation include: GSK598809 (DRUG).
Who is sponsoring clinical trial NCT00605241?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.